Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v2.4.0.6
Subsequent Events (Details) (USD $)
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jul. 12, 2012
Business Acquisition [Line Items]      
Business acquisition effective date Jul. 12, 2012    
Number of shares issuable to acquire business (in shares) 236,433    
Vesting period of equity awards 4 years    
Acquisition agreement date Jun. 29, 2012    
Number of clinical and scientific advisors 50    
CollabRx, Inc. [Member]
     
Business Acquisition [Line Items]      
Loss from continuing operations $ (1,246,000) $ (1,381,000)  
Loss from discontinued operations, net of taxes (1,000) (2,000)  
Net loss applicable to common stockholders (1,247,000) (1,383,000)  
Basic and diluted:      
Weighted-average common shares outstanding (in shares) 1,689,000 1,689,000  
Net loss per share:      
Basic and diluted (in dollars per share) $ (0.74) $ (0.82)  
CollabRx, Inc. [Member] | Subsequent Event [Member]
     
Business Acquisition [Line Items]      
Business acquisition effective date Jul. 12, 2012    
Number of shares issuable to acquire business (in shares) 236,433    
Shares issued specified as percentage of total shares outstanding (in hundredths) 14.00%    
Fair value of common stock to be issued 932,000    
Indebtedness assumed through the issuance of promissory notes 500,000    
RSUs and options granted as "inducement grants" in acquisition (in shares)     368,417
Vesting period of equity awards 4 years    
Acquisition agreement date Jun. 29, 2012    
Number of clinical and scientific advisors 50    
"Big data" opportunity value 300,000,000,000    
Pro forma revenue $ 13,000 $ 1,000